Search clinical trials for: TA-650 6 mg/kg

Total 3436 results

Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
BioMarin Pharmaceutical

Terminated

Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Belgium, Netherlands, Italy, Sweden
NeuroBo Pharmaceuticals Inc.

Completed

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

Hypercholesterolemia
BioMarin Pharmaceutical

Terminated

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Netherlands, Belgium, Italy, Sweden
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
Daiichi Sankyo, Inc.

Completed

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

Liver Neoplasms | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer

Korea, Republic of, Taiwan, United States, Japan
Sameem M. Abedin, MD

Recruiting

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

Graft-versus-host Disease

United States
Regeneron Pharmaceuticals

Completed

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Canada
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

Behcet Syndrome | Behcet's Disease | Neuro-Behcet's Disease

Japan
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
Duke University
National Heart, Lung, and Blood Institute (NHLBI); American Heart Association

Completed

Ketone Pharmacokinetic Study in HFrEF

Heart Failure With Reduced Ejection Fraction

United States
Adynxx, Inc.
National Institute on Drug Abuse (NIDA)

Withdrawn

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores

Pain, Postoperative
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
Genor Biopharma Co., Ltd.

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer

China
Clearside Biomedical, Inc.

Completed

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis (DOGWOOD)

Uveitis, Anterior | Panuveitis | Uveitis | Macular Edema | Uveitis, Posterior | Uveitis, Intermediate

United States
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
NYU Langone Health

Completed

TA-65 Pharmacokinetic Study

Healthy

United States
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
ViGenCell Inc.

Not yet recruiting

A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

Graft Versus Host Disease
Adynxx, Inc.

Withdrawn

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

Pain, Postoperative

United States
Merck Sharp & Dohme LLC

Terminated

Treatment With Infliximab in a Medical Setting (Study P05587) (OPTIMIST)

Crohn's Disease
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
Adynxx, Inc.

Completed

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Post-surgical Pain

United States
Janssen Research & Development, LLC

Terminated

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
Merck Sharp & Dohme LLC

Completed

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

Staphylococcal Infection
Oxford Cannabinoid Technologies Holdings PLC
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Healthy

United Kingdom
University of Connecticut

Completed

Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

Metabolic Syndrome X

United States
University of Texas Southwestern Medical Center
GlaxoSmithKline

Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Breast Cancer

China
Medical College of Wisconsin
Miltenyi Biomedicine GmbH

Active, not recruiting

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

Search clinical trials for: TA-650 6 mg/kg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations